Bayer announced promising outcomes from the Phase II CONFIDENCE study, revealing that initiating finerenone alongside an SGLT-2 inhibitor significantly lowers the urine albumin-to-creatinine ratio (UACR) in patients suffering from chronic kidney disease (CKD) linked to type 2 diabetes (T2D). These findings, presented at the 62nd European Renal Association Congress, highlight the potential for enhanced kidney protection through combined medication.
Study Highlights and Results
The CONFIDENCE study involved 818 participants and demonstrated that the simultaneous use of finerenone and empagliflozin resulted in a 52% reduction in UACR by day 180. This reduction surpassed the effects of either medication alone by 29% and 32%, respectively. Remarkably, nearly 75% of patients achieved a UACR drop of over 30% within just two weeks, meeting the American Diabetes Association’s threshold for slowing CKD progression.
Safety and Patient Outcomes
Safety profiles remained consistent with individual treatments, and benefits were observed across diverse patient subgroups. The early and additive reduction in UACR suggests significant advantages in managing CKD and reducing cardiovascular risks associated with T2D. These results support the strategy of early combination therapy to optimize patient outcomes.
Inferences:
- Combined therapy may become a standard approach for CKD management in T2D patients.
- Early intervention with dual therapy could significantly slow disease progression.
- Healthcare providers might prioritize simultaneous prescription of finerenone and SGLT-2 inhibitors.
The CONFIDENCE study’s success underscores Bayer’s commitment to advancing treatments for chronic kidney and cardiovascular diseases. By demonstrating the efficacy of dual therapy, the research paves the way for improved clinical practices and better long-term health outcomes for millions affected by T2D and CKD worldwide.
Bayer continues to lead in cardiology and kidney disease treatment innovations, aiming to address significant unmet medical needs. The company’s extensive clinical programs and diverse medication portfolio reflect a strategic focus on precision medicine, ensuring that patients receive the most effective and personalized care available.
These developments offer valuable insights for patients and healthcare professionals alike, emphasizing the importance of integrated treatment approaches in managing complex chronic conditions. As Bayer expands its research and development efforts, the potential for new therapeutic solutions grows, promising a healthier future for those battling kidney and cardiovascular diseases.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
